



MINISTÈRE  
DE L'ENSEIGNEMENT  
SUPÉRIEUR  
ET DE LA RECHERCHE

*Liberté  
Égalité  
Fraternité*



Cycle de présentation des appels à projets  
du programme de travail santé 2023-2024

## Les appels de la DESTINATION 3 – Infectieux

Vania Rosas, MESR  
[pcn-sante@recherche.gouv.fr](mailto:pcn-sante@recherche.gouv.fr)




# Netiquette

- ✓ Éteignez votre microphone et vidéo pendant le webinaire pour ne pas bloquer la bande passante
- ✓ Posez vos questions dans le chat : vous pouvez poser vos questions à la fin de chaque topic

# Dans ce webinaire vous allez trouver:

---

- 
- Qui sommes nous ?
  - Planification stratégique 2021-2024
  - Comment participer à un projet Horizon Europe en Santé
  - Destination 3
  - Appels « infectieux » de la Destination 3

# PCN Santé – Qui sommes-nous ?



**Virginie Sivan, MESRI**

Coordination PCN et représentation au comité de programme Santé



**Vania Rosas-Magallanes**




**Sophie Decamps**



**Catherine Tostain-Desmares**



Nous contacter : [pcn-sante@recherche.gouv.fr](mailto:pcn-sante@recherche.gouv.fr)

Nous suivre : LinkedIn 

Liste de diffusion

# Le Cluster Santé

## 6 domaines d'intervention



## Planification stratégique 2021-2024\*

Priorités politiques de l'UE (Transition verte et numérique)  
Orientations Stratégiques pour la R&I  
"Expected impacts" – Destinations (Santé)



**Programme de travail  
Santé**



**Partenariats en santé**



**Mission Cancer**

# Participer au Cluster Santé

## ☑ Qu'est ce qu'un projet collaboratif ?

Consortium de partenaires réunis pour mener à bien un projet collaboratif et **multidisciplinaire** de recherche et développement, avec un **impact à la fois sociétal** au bénéfice du citoyen (et des patients) et **économique sur les systèmes de santé**.

## ☑ Financement d'un consortium

- **Coordinateur** : seul interlocuteur de la CE, assure le bon déroulé du projet et de ses livrables, et l'interaction entre les partenaires.
- **Partenaire (Bénéficiaire)** : responsable d'un *work-package* ou d'une activité



5 à 20 à partenaires



Budget 3 à 15M€



4 à 5 ans

# Types d'action

---

## ☑ RIA - Research and Innovation Actions

→ recherche fondamentale et appliquée, développement et l'intégration de technologie, essais et validation d'un prototype à petite échelle dans un laboratoire ou un environnement simulé

**Taux de financement européen 100%**

## ☑ IA - Innovation Actions

→ prototypage, essais, démonstration ou pilotes, validation du produit à grande échelle, première commercialisation. Les projets peuvent inclure des activités limitées de recherche et de développement

**Taux de financement européen  
100% pour les entités publiques - 70% pour les entités privées**

## ☑ CSA - Coordination and Support Actions

→ études de design pour de nouvelles infrastructures, activités complémentaires de planning stratégique, mise en réseau et la coordination entre programmes dans différents pays

**Taux de financement européen 100%**

---

# Règles de participation

---

## ✔ Conditions d'éligibilité d'un consortium

Minimum 3 entités légales indépendantes et établies dans un Etat Membre ou Etat Associé différent, **dont au moins une établie dans un Etat Membre**

## ✔ Condition de participation

Toute entité légale de tout pays peut participer (organisme de recherche, université, PME, associations, villes...)

## ✔ Pays éligibles au financement

Etats Membres et états associés à Horizon Europe

Certains pays tiers:

- Pays à revenus faibles ou intermédiaires
  - Pays spécifiés dans les appels
  - **USA (pour le programme santé uniquement)**
-



# Coopération internationale

Toutes les lignes d'appel sont ouvertes à la coopération internationale

## ☑ Contribution financière de la C.E pour le Cluster Santé

- 27 Etats-Membres
- Etats-Associés :
  - Albanie, Arménie, Bosnie-Herzégovine, Îles Féroé, Géorgie, Islande, Israël, Kosovo, Maroc, Moldavie, Monténégro, Macédoine du Nord, Norvège, Serbie, Tunisie, Turquie et Ukraine.

ATTENTION : UK – association en cours - (possible de les associer à un projet en montage en attendant l'entrée en vigueur de l'association)

- Pays-Tiers : certains pays à faibles et moyens revenus sont automatiquement éligibles au financement (Programme Guide Horizon Europe)

## ☑ CAS PARTICULIER

USA : partenaires USA éligibles au financement par la CE uniquement pour le cluster Santé dans le cadre d'un accord de réciprocité avec le NIH → USA pas éligible au financement dans la mission Cancer

Suisse: pas d'accord d'association. Les institutions Suisses sont financées directement par leur agence nationale.

# Structure d'un appel à projets

---

## Destination n°3 : Titre de la destination

Description de la destination avec un état des lieux et des objectifs à atteindre

### **Expected Impact** : → **Long terme**

Liste d'impacts en lien avec le plan stratégique que les propositions de l'ensemble des topics de cette destination doivent contribuer à atteindre.

## Topic 3.1 : Titre du topic

- **Expected outcomes** : les résultats attendus des projets soumis en réponse à ce topic doivent y contribuer → **Court/moyen terme**
- **Scope** : périmètre d'action des propositions soumises dans le cadre de ce topic

## Topic 3.2 : Titre du topic

- **Expected outcomes** : les résultats attendus des projets soumis en réponse à ce topic doivent y contribuer
  - **Scope** : périmètre d'action des propositions soumises dans le cadre de ce topic
-



# Cluster Santé : WP 2023-2024

---

---

# Programme de travail 2023-2024

---



1- **Staying healthy** in a rapidly changing society



2- Living and working in a **health-promoting environment**



3- **Tackling diseases** and reducing disease burden



4- Ensuring **access to innovative, sustainable and high-quality health care**



5- Unlocking the full potential of **new tools, technologies and digital solutions** for a healthy society



6- Maintaining an innovative, sustainable and globally **competitive health-related industry**

---

# Destination 3 : Tackling diseases and reducing diseases burden

---



## Objectives :

- i) Better understanding of diseases, their drivers and consequences, including pain and the causative links between health determinants and diseases, and better evidence-base for policymaking;
- ii) better methodologies and diagnostics that allow timely and accurate diagnosis, identification of personalised treatment options and assessment of health outcomes, including for patients with a rare disease;
- iii) development and validation of effective intervention for better surveillance, prevention, detection, treatment and crisis management of infectious disease threats;
- iv) innovative health technologies developed and tested in clinical practice, including personalised medicine approaches and use of digital tools to optimise clinical workflows;
- v) new and advanced therapies for non-communicable diseases, including rare diseases developed in particular for those without approved options, supported by strategies to make them affordable for the public payer; and
- vi) scientific evidence for improved/tailored policies and legal frameworks and to inform major policy initiatives at global level

**Contexte politique :** EU Action on Antimicrobial Resistance, Europe's Beating Cancer Plan, Steering group on prevention and promotion, WHO Global Action Plan for the Prevention and Control of NCD. HERA work plan

---

# Destination 3 : Tackling diseases and reducing diseases burden

---



## Expected impacts

- Health burden of diseases is **reduced**, patient are **diagnosed** early and accurately and receive effective, cost-efficient and affordable treatment
  - Premature mortality from NCD is **reduced by one-third**, mental-health and well-being is promoted
  - **Health care systems benefit from strengthened R&I**, human capacities and know-how for combatting communicable and non-communicable diseases. They are better prepared to respond rapidly and effectively to health emergencies
  - **Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens**
  - **Patients and citizens are knowledgeable of disease threats**, involved and empowered to make decisions for their health
  - **The EU benefit from high visibility**, leadership and standing in international fora on global health
-

# HERA : Health Emergency Preparedness and Response Authority

---

**Agence mise en place suite à la pandémie COVID-19, créée en Septembre 2021**

**Objectif** : Prévenir et détecter les urgences sanitaires et y faire face rapidement en Europe:

- Anticiper les menaces et crises sanitaires potentielles
- Assurer la disponibilité et l'accès aux principales contre-mesures médicales: mise au point, production et distribution de médicaments, de vaccins et d'autres contre-mesures médicales (gants, masques, etc.)

Pas de budget en propre mais mise en œuvre d'actions via les budgets disponibles dans les programmes de financements européens existants, dont le Cluster Santé d'Horizon Europe pour le volet R&I en santé, entre autres

---

# HERA and its main tasks

## PREPAREDNESS MODE



Threat assessments and intelligence gathering



Advanced research and development capacities for MCMs



Production capacities for MCMs



Procurement, stockpiling, and distribution capacities for MCMs



Knowledge and skills capacity building

## CRISIS MODE



Monitoring of crisis-relevant MCMs



Procurement, purchase and manufacturing of crisis-relevant MCMs



Activation of EU FAB facilities



Activation of emergency research and innovation plans



Establishment of an inventory of crisis-relevant MCM production facilities



Activation of emergency funding

International collaboration



## Destination 3 : Tackling diseases and reducing diseases burden



Topic	Date limite	Type	Budget par projet	Nbre projets financés
<b>Call – Tackling diseases (Single stage - 2023)</b>				
2023-DISEASE-03-04: <u>Pandemic preparedness and response</u> : Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential	13 Avr. 2023	RIA	7-8 M€	7
2023-DISEASE-03-05: <u>Pandemic preparedness and response</u> : Sustaining established coordination mechanisms for European adaptive platform trial network and cohort network	13 Avr. 2023	CSA	1-2 M€	2
2023-DISEASE-03-07: Relationship between infections and non-communicable diseases	13 Avr. 2023	RIA	6-7 M€	5
2023-DISEASE-03-17: <u>Pandemic preparedness and response</u> : Understanding vaccine induced-immunity	13 Avr. 2023	RIA	7-8 M€	5
2023-DISEASE-03-18: <u>Pandemic preparedness and response</u> : Immunogenicity of viral proteins of viruses with epidemic potential	13 Avr. 2023	RIA	7-8 M€	7

## Destination 3 : Tackling diseases and reducing diseases burden



Topic	Date limite	Type	Budget par projet	Nbre projets financés
<b>Call – Tackling diseases (Two stage - 2024)</b>				
2024-DISEASE-03-11-two-stage: <u>Pandemic preparedness and response</u> : Adaptive platform trials for pandemic preparedness	19 Sep. 2023 11 Avr. 2024	RIA	8-10 M€	3
2024-DISEASE-03-14-two-stage: Tackling high-burden for patients, under-researched medical conditions	19 Sep. 2023 11 Avr. 2024	RIA	6-7 M€	4
<b>Call – Tackling diseases (Single stage - 2024)</b>				
2024-DISEASE-03-12: <u>Pandemic preparedness and response</u> : Maintaining the European partnership for pandemic preparedness	11 Avr. 2024	CSA	2 M€	1
2024-DISEASE-03-20: <u>Pandemic preparedness and response</u> : Host-pathogen interactions of infectious diseases with epidemic potential	11 Avr. 2024	RIA	7-8 M€	5

# HORIZON-HLTH-2023-DISEASE-03-04: Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

---

**Aim:** develop and advance broad-spectrum anti-viral compounds and develop novel approaches to the development of such compounds, which target viruses with high epidemic or pandemic potential for the EU

## All of the following expected outcomes :

- **The scientific and clinical communities** have an increased knowledge on viruses with epidemic potential and in particular a **better understanding of different potential mechanisms of action** for the development of broad-spectrum anti-viral therapeutics for these viruses.
- **The scientific and clinical communities** have access to **novel approaches for the development of anti-viral therapies** for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
- **The scientific and clinical communities** have access to experimental **broad-spectrum antiviral candidates** against emerging or re-emerging viral infections for further clinical investigation.
- A diverse and robust **pipeline of broad-spectrum anti-viral drug candidates** is available for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic.

Date limite de soumission  
13 avril 2023

Budget total : 50 M€  
Budget par projet : 7-8 M€  
Type d'action : RIA

# HORIZON-HLTH-2023-DISEASE-03-04: Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

---

**Eligible viruses** : Viruses with higher epidemic or pandemic potential such as the one from WHO list and meeting the criteria identified by HERA

Viruses for which there are no currently available effective therapeutics or for which the therapeutics available are sub-optimal

**Innovation stage** : Preclinical work and proof-of-concept/first-in-human studies and early safety and efficacy trials (Phase I/II excluded). Innovative delivery systems

## Key aspects

- Incorporate state-of-the-art **screening technology** and innovative approaches to identify new targets for antiviral compound development
- Emphasis should be put on the research and development of broad-spectrum antivirals, which **may include repurposing** of previously approved or in-pipeline drugs.
- Application of novel approaches and widely applicable workflows (e.g. **artificial intelligence**) for rapid and reliable identification of broad-spectrum anti-viral therapeutics.

# HORIZON-HLTH-2023-DISEASE-03-04: Pandemic preparedness and response: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential

---

## Should include in the consortium:

- Regulatory bodies
- Research and Clinicians
- Bioinformaticians



## Examples of funded H2020 projects (liste non exhaustive)

**Fight-nCoV** - FIGHTING-OFF CORONAVIRUS (SARS-CoV-2) WITH BROAD-SPECTRUM ANTIVIRALS: ESTABLISHING ANIMAL VIRAL CHALLENGE MODEL

**INITIATE** - INnate-ImmunoTabollsm as Antiviral TargEt

<https://cordis.europa.eu/>

---

## HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trial network and cohort network

---

**Aim:** maintaining and strengthening existing strategic coordination mechanisms across adaptive platform trials and across cohort studies in Europe and beyond for avoiding redundancies,

### All of the following expected outcomes

- **The research community** sustains **appropriate coordination mechanisms** 1) among different EU-wide adaptive platform trials and/or 2) among established cohorts in Europe and beyond with a view for better pandemic preparedness and response,
- The adaptive platform trial and/or the cohort networks **maximise coordination and harmonisation of their respective studies** within their relevant network for maximum research efficiency and optimal evidence generation.
- The European adaptive platform trial and/or the cohort networks **coordinate with the European Pandemic Preparedness Partnership** and are well connected to each other and to relevant other regional and global initiatives.

Date limite de soumission  
13 avril 2023

Budget total : 3 M€  
Budget par projet : 1-2M€  
Type d'action : CSA

---

# HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trial network and cohort network

---

## Key aspects

- **Clinical research preparedness**
  - **Describe a coordination mechanism** for adaptive platform trials and/or for cohort research.
  - Developing a **common approach for the European clinical research** to enable pragmatic solutions to shared challenges across European clinical trials and/or cohorts for pandemic preparedness and response
  - Optimal use of resources
-

## **HORIZON-HLTH-2023-DISEASE-03-05: Pandemic preparedness and response: Sustaining established coordination mechanisms for European adaptive platform trial network and cohort network**

---

### **Consortium**

- European stakeholders, such as representatives from **regulatory authorities, industry, policymakers, patient organisations**, etc., as well as relevant non-European networks and stakeholders
- Links to **HERA** and Pandemic preparedness partnership, the European Medicines Agency (**EMA**) and the European Centre for Disease Prevention and Control (**ECDC**) actions, **HORIZON-INFRA-2023-DEV-01-01**, global initiatives such as the Global Research Collaboration for Infectious Disease Preparedness (**GloPID-R**), the Global Health **EDCTP3** Joint Undertaking, or the World Health Organization (WHO).

### **Complementarities with the following funded projects:**

<https://covid19trials.eu/>

<https://vaccelerate.eu/>

<https://www.ecraid.eu/>

---



# HORIZON-HLTH-2023-DISEASE-03-07: Relationship between infections and non-communicable diseases

---

**Aim:** Elucidate and provide a better understanding of causative links between infections and non-communicable diseases onsets and comorbidities, and/or the impact of infections on the exacerbation of existing NCDs or vice versa, in children and/or adults

## Contributing to the following expected outcomes

- **All players along the health care value chain** are provided with new knowledge for a **better understanding of the links** (e.g. causalities) between infectious diseases (IDs) and non-communicable diseases (NCDs) and comorbidities, including **knowledge on host risk factors** that impact the development of disease progression for NCDs and/or Infectious Diseases.
- **Researchers and clinicians** are provided with a **robust evidence** base that will contribute to the development of new or improved tools to diagnose and prevent the development and aggravation of non-communicable disease(s) as well as early treatment and management of patients suffering from co-morbidities following an infectious disease.
- **Healthcare practitioners** have access to **knowledge to guide them on preventive measures**, on early identification of diseases onset and of those patients at risk of developing severe disease progression, and on the optimal treatment of patients.

Date limite de soumission  
13 avril 2023

Budget total : 30 M€  
Budget par projet : 6-7 M€  
Type d'action : RIA

# HORIZON-HLTH-2023-DISEASE-03-07: Relationship between infections and non-communicable diseases

---

**Eligible areas** : any infection including those with pandemic potential (viral, bacterial, or fungal) with non-communicable diseases of major importance.  
Research on cancer is excluded

**Innovation stage** : Preclinical research, observational studies and/or clinical studies can be considered for this topic. Proposals could include patient follow-up to identify conditions that may appear only after a patient has recovered from the infectious disease.

## Key aspects

- The analysis of **genetics, immune status, immune or inflammatory responses, microbiome, lifestyle** and/or other relevant factors (e.g. differences in age, sex/gender, vaccination status, ethnicity) should be integrated to get information for prevention, early diagnosis, risk factors, and to better understand causative links as well as the progression of those non-communicable diseases
  - Special attention should be given to **vulnerable individuals**, such as those with known existing preconditions.
  - The applicants are encouraged to incorporate **artificial intelligence (AI)** tools that enable advanced quality data analysis and for assessing and predicting the risk of developing a disease and/or the risk of disease progression/severity where relevant.
-

# HORIZON-HLTH-2023-DISEASE-03-07: Relationship between infections and non-communicable diseases

---

## The consortium should include:

- Researchers and Clinicians
- Patients
- Healthcare practitioners
- Artificial intelligence experts/ bioinformaticians
- Public health authorities
- Projects including COVID-19 and post COVID-19 infection are encouraged
- Links to relevant EU-funded projects, such as ORCHESTRA[[ <https://orchestra-cohort.eu/>]].

<https://cordis.europa.eu/>



# HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response:

## Understanding vaccine induced-immunity

---

**Aim** : Study vaccine-induced immunity in the general population and vulnerable groups. Improve the global vaccine research and development pipeline for emerging and re-emerging viral infections, and to strengthen the current leading role of the EU in vaccine development,

**All of the following expected outcomes :**

- **The scientific and clinical communities** have an increased **knowledge of vaccine-induced immunity** and, in particular, a **better understanding of factors** that affect the magnitude, breadth, nature and duration of immunity to vaccine antigens.
- **The scientific and clinical communities** have an increased **knowledge of the durability and breadth of vaccine-induced immunity in vulnerable populations and older age groups**.
- **The scientific and clinical communities** have an increased **knowledge of correlates of protection for pathogens** with epidemic potential to allow the development of effective vaccines.
- **The scientific and clinical communities** have an increased **knowledge of the characteristics that influence vaccine effectiveness** to allow for novel approaches for the development of vaccines for emerging and re-emerging infections, including antigenic variants, in the context of epidemic and pandemic preparedness.

Date limite de soumission  
13 avril 2023

Budget total : 20 M€  
Budget par projet : 7-8 M€  
Type d'action : RIA

# HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response: Understanding vaccine induced-immunity

---

**Eligible areas** : Viruses meeting the criteria for pathogens with high pandemic potential as identified by HERA

## Key aspects

- Look both at the **magnitude and breadth of initial immune responses and the duration of immunity** after vaccination with different vaccine types (mRNA, vector, inactivated, subunit, attenuated,...).
  - Assess how **sex** (e.g. male vs female, pre-vs-postmenopausal), **age** (childhood vs adolescent vs elderly) **and/or lifestyle** (e.g. obesity, drug addiction, diet, sport) affect the immune response
  - Examine genetic and other molecular **factors that may influence immune response in humans**. Proposals should pursue a multi-omics approach in order to foster a deep understanding of vaccine induced immunity.
  - Proposals should also **assess how pre-existing conditions or chronic infections influence the immune response**.
  - Vulnerable groups
-

# HORIZON-HLTH-2023-DISEASE-03-17: Pandemic preparedness and response: Understanding vaccine induced-immunity

---

## Consortium should include:

- Researchers and Clinicians
- Social Sciences and Humanities experts
- Links to HERA

<https://cordis.europa.eu/>



# HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic potential

---

**Aim** : provide innovative approaches with the aim to diversify and accelerate the global pandemic preparedness research and development pipeline for emerging and reemerging viral infections - identify targets for optimal vaccine design

**All** of the following expected outcomes :

- **The scientific and clinical communities** have an increased knowledge on viruses with epidemic and pandemic potential and in particular a **better understanding of viral targets** for vaccine development.
- **The scientific and clinical communities** have access to **novel approaches for the prevention and treatment** for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
- **The scientific and clinical communities** have access to **experimental vaccine candidates** against emerging or re-emerging viral infections for further clinical investigation.
- A **diverse and robust pipeline of vaccine candidates** is available for emerging and reemerging viral infections, increasing therapeutic options for clinical deployment

Date limite de soumission  
13 avril 2023

Budget total : 50 M€  
Budget par projet : 7-8 M€  
Type d'action : RIA

# **HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response:** **Immunogenicity of viral proteins of viruses with epidemic potential**

---

**Eligible viruses** : Hendra and Nipah Virus, Lassa virus, Crimean Congo haemorrhagic fever virus, Rift Valley fever virus, Ebola and Marburg virus, Dengue virus, Yellow Fever virus, Zika virus, West Nile fever virus and Chikungunya virus

**Pathogens where information on host-pathogen interaction and viral surface structures is already available**

**Innovation stage** : Preclinical work and if possible, proof-of-concept/first-in-human studies in humans of the vaccine candidate

## **Key aspects**

- Identification of key antigenic targets for the priority pathogens
  - Improvement or, if necessary, establishment of animal models for the testing of vaccine candidates where alternative models are not available.
  - Characterization of the immunogenicity of antigenic targets in appropriate animal or alternative models and in pre-clinical tests.
-



# **HORIZON-HLTH-2023-DISEASE-03-18: Pandemic preparedness and response: Immunogenicity of viral proteins of viruses with epidemic potential**

---

## **Consortium should include:**

- Researchers and clinicians
- Vaccine developers (pipelines for deployment)

<https://cordis.europa.eu/>



# **HORIZON-HLTH-2024-DISEASE-03-11-two-stage: Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness**

---

**Aim** : provide funding to adaptive clinical platform trials that may be implemented routinely **outside of an epidemic or pandemic context**, but that are designed to be ready for the timely assessment of novel diagnostics, therapeutics or vaccines in the face of an epidemic or pandemic.

**All of the following expected outcomes:**

- **A diverse and comprehensive EU landscape of multi-country adaptive platform trials** (i.e. able to study multiple interventions in a disease or condition in a perpetual manner, thus allowing modification to the trial after its initiation without undermining its validity and integrity) that assess vaccines and therapeutics for infectious diseases and have the capacity to pivot rapidly in the case of epidemic or pandemic health threats.
  - **Innovative and improved design of clinical studies**, suited for pandemic preparedness, is available for the clinical research community, taking into account the high safety standards in the European regulatory environment.
  - **Trial sites across multiple countries** have the capacity to deliver robust clinical evidence in a diverse European population, using harmonised research methods, data collection and analysis.
- 

**Stage 1 : 19 Sep. 2023**

**Stage 2 : 11 Avr. 2024**

Budget total : 30 M€

Budget par projet : 8-10 M€

Type d'action : RIA

# HORIZON-HLTH-2024-DISEASE-03-11-two-stage: Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness

---

## Key aspects

- Development of **robust clinical evidence** that contributes to the knowledge base for the diagnosis, treatment and prevention of infectious diseases. Sex, gender, age, ethnicity and socio-economic factors should be taken into account.
  - Known hurdles related to **ethical, administrative, regulatory, legal and logistical** aspects should be anticipated and addressed to the extent possible, in order to avoid such barriers when the trial needs to pivot in response to an epidemic or pandemic.
  - Engagement with **clinical researchers and biostatisticians**, to increase capacity for the design and implementation of adaptive platform trials across Europe.
-

# **HORIZON-HLTH-2024-DISEASE-03-11-two-stage: Pandemic preparedness and response: Adaptive platform trials for pandemic preparedness**

---

## **Consortium**

- Researchers, clinicians, social sciences and humanities experts
- European stakeholders, such as representatives from **regulatory authorities, industry, policymakers, patient organisations**, etc., as well as relevant non-European networks and stakeholders
- Links to **HERA** and Pandemic preparedness partnership, the European Medicines Agency (**EMA**) and the European Centre for Disease Prevention and Control (**ECDC**) actions, **HORIZON-INFRA-2023-DEV-01-01**, global initiatives such as the Global Research Collaboration for Infectious Disease Preparedness (**GloPID-R**), the Global Health **EDCTP3** Joint Undertaking, or the World Health Organization (WHO).

## **Complementarities with the following funded projects:**

**<https://covid19trials.eu/>**

**<https://vaccelerate.eu/>**

**<https://www.ecraid.eu/>**



# HORIZON-HLTH-2024-DISEASE-03-14-two-stage: Tackling high-burden for patients, under-researched medical conditions

---

**Aim :** Address the gaps in robust, scientific evidence for improved policies and practices to tackle such medical condition(s) and aim at identifying the pathophysiological mechanism(s) and potential risk factors of the medical condition(s). These efforts should underpin the development of diagnostics, therapeutics, and/or preventive strategies for the condition

## **Most of the following outcomes:**

- **The scientific and clinical communities** make effective use of state-of-the-art information, data, technologies, tools and best practices to better understand the condition, underpinning the development of diagnostics, therapeutics and/or preventive strategies.
- **The scientific and clinical community** exchange data, knowledge and best practices, thereby strengthening their collaboration and building knowledge and care networks in Europe and beyond.
- **The scientific and clinical community** make wide use of newly established and where relevant open access databases and/or integrate them with existing infrastructures for storage and sharing of collected data according to FAIR principles, thereby encouraging further use of the data.
- **Policymakers and funders** are informed of the research advances made and consider further support in light of the sustainability of the studies.
- **Patients and caregivers** are constructively engaged with the research, which also caters for their needs.
- **Health professionals** have access to and use improved clinical guidelines on diagnosis and/or treatment of the condition.

**Stage 1 : 19 Sep. 2023**

**Stage 2 : 11 Avr. 2024**

Budget total : 25 M€

Budget par projet : 6-17 M€

Type d'action : RIA

# HORIZON-HLTH-2024-DISEASE-03-14-two-stage: Tackling high-burden for patients, under-researched medical conditions

---

**High burden medical conditions** : include those that are either life-threatening or lead to chronic invalidity or a severely reduced quality of life

Under-researched even though with high-prevalence (**rare diseases excluded**)

**Example of diseases : Lyme disease**

**Innovation stage** : Basic, pre-clinical and/or clinical research

## Key aspects

- Address the gaps in robust, scientific evidence for improved policies and practices to tackle such medical condition(s), and aim at identifying the pathophysiological mechanism(s) and potential risk factors of the medical condition(s)
- These efforts should underpin the development of **diagnostics, therapeutics**, and/or preventive strategies for the condition.
- **Demonstrate that the medical condition(s) under study is/are insufficiently understood, inaccurately diagnosed or inadequately treated in a significant proportion of patients, and as such represent a high burden for patients and society.**
- Where applicable, the development of biomarkers and other technologies for diagnosis, monitoring in patients, and stratification of patient groups should be considered.
- Where applicable, the development of clinically relevant, **(non-)human model systems** that can complement clinical investigations should be considered.

# HORIZON-HLTH-2024-DISEASE-03-14-two-stage: Tackling high-burden for patients, under-researched medical conditions

---

## Consortium should include:

- Researchers and clinicians
- Patients associations and caregivers
- Policy makers and funders
- Health professionals
- SMEs participation encouraged
- Links to: BBMRI-ERIC research infrastructure on biobanks are encouraged

<https://cordis.europa.eu/>



# **HORIZON-HLTH-2024-DISEASE-03-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential**

**Aim :** Characterise host-pathogen interactions with a view to inhibit viral replication, viral proteases, viral exit strategies and to develop therapeutic antibodies and vaccines that target viruses with high epidemic or pandemic potential for the EU.

**All of the following expected outcomes:**

- **The scientific and clinical communities** have an increased **knowledge on viruses with epidemic potential** and in particular a **better understanding of pathogen–host interactions** for the targeted development of vaccines and inhibitors for the prevention of viral infection and the viral transmission during pathogenesis.
- **The scientific and clinical communities** have access to **novel approaches for the prevention and treatment** for emerging and re-emerging infections in the context of epidemic and pandemic preparedness.
- **The scientific and clinical communities** have **access to experimental vaccine candidates and candidates** that inhibit cellular uptake of viruses against emerging or re-emerging viral infections for further clinical investigation.

Date limite de soumission  
11 avril 2024

Budget total : 50 M€  
Budget par projet : 7-8 M€  
Type d'action : RIA



# HORIZON-HLTH-2024-DISEASE-03-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential

---

**Eligible viruses** : Hendra and Nipah virus, Lassa virus, Crimean Congo haemorrhagic fever virus, Rift Valley fever virus, Ebola and Marburg virus, Dengue virus, Yellow Fever virus, Zika virus, West Nile fever virus and Chikungunya virus

## Key aspects

- Identification and characterisation of receptors on the host cell that enable the **docking and internalisation of a virus** with a particular emphasis on the diversity of cellular entry receptors and tissue specificity.
  - Identification and characterisation of **viral surface proteins** that are capable of interacting with host target cells.
  - Characterisation of the mechanism of **viral uptake in the host cell with regards to the topology** and the dynamics of the host receptor – virus ligand interaction.
  - **Identification of receptor and ligand (sub)units that could be targeted by preventive or therapeutic intervention.**
-

# HORIZON-HLTH-2024-DISEASE-03-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential

---

## Consortium should include:

- Researchers and clinicians
  - Links to HERA
  - Joint Research Centre infrastructure on nanobiotechnology should be considered for biophysical characterization of recombinant proteins, antigens and therapeutic antibodies (budget)
  - JRC should also be considered for bridging research and regulatory aspects (budget)
  - JRC will collaborate with any successful grant (EC)
-



# Aide au montage

## ANR : MRSEI

# Montage de Réseaux Scientifiques Européens ou Internationaux

---

Soutient l'**aide au montage et à l'animation** d'un réseau scientifique européen ou international **coordonné par une équipe Française** impliquant les membres du réseau qui sera déposé à un appel européen ou international.

Subvention: 35 k€ pour une durée maximale de 24 mois

Coût éligibles:

- ☑ communication, organisation et animation de rencontres, ateliers, symposium, etc...
- ☑ prestation de service à hauteur maximale de 10 000€ pour appuyer le coordinateur dans le montage du futur projet.

Prochaines dates de soumission :

- 9 janvier 2023
- 3 avril 2023
- 1<sup>er</sup> juin 2023
- 9 octobre 2023

Toutes les infos : <https://anr.fr/fr/detail/call/montage-de-reseaux-scientifiques-europeens-ou-internationaux-mrsei-2023/>

---

# Le diagnostic Partenariat pour le projets collaboratifs des entreprises

Le Diagnostic Partenariat Technologique International (Diag PTI) de Bpifrance vise à faciliter l'accès des entreprises françaises aux appels à projets collaboratifs de recherche, développement et innovation, au premier rang desquels Horizon Europe.

## En pratique, le Diag PTI comprend



- une multitude de possibilités d'accompagnement sur toute la partie de montage du projet collaboratif : recherche de partenaires, négociation de l'accord de consortium, écriture de dossier, etc.
- une subvention qui couvre 50 % du montant TTC de la prestation d'un Expert Conseil
- une prestation adaptée aux besoins de l'entreprise : jusqu'à 25k€ HT si l'entreprise est cheffe de file, jusqu'à 5k€ HT si l'entreprise fait partie d'un consortium sans en être à la tête
- un dépôt au fil de l'eau, qui s'adapte à la timeline de l'entreprise
- une demande facilitée en ligne, sur le site de Bpifrance
- une réponse rapide sous 2 semaines

# Devenez Expert Evalueateur

HORIZON 2020

Toutes les informations et webinaire de présentation :

<https://www.horizon-europe.gov.fr/devenez-expert-evaluateur-horizon-europe-aupres-de-la-commission-europeenne-24364>

## Pourquoi devenir expert ?

- ▶ S'approprier le mécanisme d'évaluation et affiner ses compétences en matière de rédaction de propositions ;
- ▶ Se faire connaître de la C.E. comme un expert du domaine ;
- ▶ Réaliser un état de l'art de la recherche européenne dans un secteur donné ;
- ▶ Développer un réseau de partenaires potentiels ;
- ▶ Mieux connaître les mécanismes européens ;
- ▶ Promouvoir sa perspective sur les enjeux de la recherche

## Qui peut être expert ?

Peuvent prétendre à devenir experts, les individus de toute nationalité, bénéficiant d'un haut niveau d'expertise dans un domaine relatif à une thématique d'Horizon 2020, qu'ils proviennent de la sphère académique, de la recherche ou de la sphère économique et commerciale.

### 4 Critères de sélection des experts

- Expertise : technique, et/ou gestion de projet, et/ou innovation, et/ou exploitation, et/ou dissémination, et/ou communication, et/ou "business development"
- Diversité géographique
- Parité
- Rotation/renouvellement : 30% par an

## En quoi consiste le travail d'évaluation ?

- ▶ Examiner et évaluer des propositions déposées dans le cadre des appels ;
- ▶ Travailler :
  - dans le cadre de sessions courtes d'une durée maximale de 10 jours par an ;
  - à distance et/ou à Bruxelles ou Luxembourg

Le nombre de propositions à traiter est variable selon l'appel



## Rémunération

Il s'agit d'une indemnité de 450 euros TTC/jour  
Prise en charge des frais de mission

## Déplacements à prévoir

L'expert évaluateur doit prévoir 1 semaine de travail et de déplacement à Bruxelles ou Luxembourg par campagne d'évaluation.

**19 January : Info day CE santé (on line):** <https://research-innovation-community.ec.europa.eu/events/2zRJQrIdbL7rCriIJBbBN4I/overview>

**20 January : Brokerage event santé CE (on line):** <https://www.horizon-europe.gouv.fr/cluster-sante-et-mission-cancer-horizon-europe-brokerage-event-appels-2023-34147>

**09 February: Lump Sum Funding in Horizon Europe: How does it work? How to write a proposal?**  
<https://ec.europa.eu/research/participants/docs/h2020-funding-guide/other/event230209.html>

**16 January: Appels Destination 6:** <https://www.horizon-europe.gouv.fr/cluster1-16-01-2023>

<https://www.horizon-europe.gouv.fr/les-shs-dans-le-programme-sante-34477>

**Contact your support services Europe**  
**Contact the Health NCPs: [pcn-sante@recherche.gouv.fr](mailto:pcn-sante@recherche.gouv.fr)**

